• Press Releases
  • In the News
  • Additional Partnership
  • Blog
  • Webinars

November 19, 2021

Tempus Signs Strategic Collaboration Agreement with AstraZeneca to Advance Oncology Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capa...

November 18, 2021

Tempus Accelerates its EHR Integration Scope with Epic

Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless...

November 16, 2021

Tempus Incorporates OncoKB Data and NCCN Guidelines Into Its Clinical Reports

Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips   Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memori...

November 8, 2021

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics...

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

October 26, 2021

Tempus Introduces A New, Predictive Diagnostic Test to its Growing Collection of Algorithms

Tempus’ platform brings research to life with predictive algorithms that screen cancer patients for mutations in the DPYD gene Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. The tes...

September 9, 2021

‘Molecular Twin’ Initiative Will Help Advance Precision Cancer Treatment

Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each...

August 17, 2021

Tempus Submits PMA Application to the FDA for its xT-Onco Assay

Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA).  Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro diagn...

August 4, 2021

Tempus Announces New Genomic Sequencing Lab in Research Triangle Park in Durham, NC

Tempus, a leader in artificial intelligence and precision medicine, today announced its new, state-of-the-art genomic sequencing lab in Durham’s Research Triangle Park (RTP). The 52,000-square foot space marks Tempus’ third laboratory, joining the company’s existing CAP-accredited/CLIA-certified labs in Atlanta and its Chicago headquarters.  RTP’s proximit...

July 28, 2021

Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Study

Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology...

Tempus Unveils Its Scalable Tumor Organoid Screening Platform  In Cell Reports Study

July 12, 2021

Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in npj Precision Oncology Study

Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity an...

Show More